Forensic Analysis · Healthcare / Pharmaceuticals / Biotech · as of Aug 12, 2026
Orasure Technologies Inc (OSUR)
A forensic read on Orasure Technologies Inc built from its complete SEC filings — financial-health screens, earnings quality, red flags and a price-aware rating. Reproducible math, not opinion.
F · Poor — capital at risk
Forensic grade
Safe
Financial health
5.5
Distress distance
Clean
Earnings quality
6
Forensic signals
-5.9
P / E (ttm)
-20.2%
ROE
$268M
Market cap
0.00%
Dividend yield
-38.1%
Revenue growth
This free snapshot doesn't read filing or proxy text, so the auditor-quality and governance checks that can lower a grade were not evaluated (red flags, auditor quality, say on pay, board independence). Those checks only ever lower a grade, so the full analysis can land below the grade above but never above it — treat it as the most favourable reading, not the settled one.
Orasure Technologies Inc earns an F (Poor — capital at risk) forensic quality grade, and its balance-sheet distress test reads 5.5, placing it in the Safe zone. 6 forensic signals were flagged in its latest SEC filings, led by inventory days.
What the filings flag
178d
FY2024→FY2025
Inventory days.Days inventory outstanding moved from 140 to 178 FY2024→FY2025 (against cost of goods sold; inventory -9% vs -37% in cost of sales). Inventory is outrunning what's being sold — a flag for softening demand or obsolescence risk ahead.
-34.6%
FY2025
Return on invested capital.Return on invested capital is -34.6% in the latest fiscal year and slipping from -6% — well below its ~10% cost of capital, so reinvested dollars may be destroying value, not building it.
FCF ($53M)
FY2025
Shareholder returns.Returned $15M to shareholders (buybacks + dividends) in FY2025, but free cash flow was ($53M) after capex — there was no free cash flow to fund the payout from at all, and operating cash flow itself was negative or zero that year too. The entire return is coming from debt or cash reserves, not cash the business itself generated — a harder case than returns merely running ahead of free cash flow, since here there was none to run ahead of.
73d DSO
FY2024→FY2025
Receivables vs revenue.Days sales outstanding moved from 63 to 73 days FY2024→FY2025 (receivables -7% vs revenue -38%). Receivables are creeping up relative to sales. Across FY2021–FY2025 the day count ran 66 → 55 → 50 → 63 → 73 days, so the latest reading sits on top of a record that was flat or falling before it — one year's move, not a direction the business has been travelling in.
+0.4%/yr
FY2022–FY2025
Key fundamentals
Latest Revenue$115.0M
Revenue Growth YoY-38.1%
Net Margin-59.8%
Free Cash Flow-$53.2M
Return on Equity-20.2%
The forensic grade and screens above are free — no account needed. Want the AI investment read on top — the 0–100 rating, thesis, bull-vs-bear, red flags and the 12-month scenario, written from Orasure Technologies Inc's actual 10-K/10-Q/8-K filings?
Diluted share count changed +1% over the last 3 years to FY2025 (+0.4%/yr). Roughly flat — buybacks ($15M) are about offsetting stock comp ($10M), not shrinking the count. Per-share value isn't being meaningfully helped or hurt by the count.
$4M
FY2022–FY2022
Goodwill impairments.Took $4M of goodwill writedowns across 1 year (FY2022 ($4M)). Writedowns mean past acquisitions underperformed what was paid for them.